These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 35299062)

  • 1. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
    Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA
    J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Altebainawi AF; AlFaifi M; Nahari M; Almagthali A; Thabit AK; Alhajaji R; Alharbi R; Kahtani K; Alenazi AA; Alharbi A; Alghwainm MM; Alotaibi SM; Alghamdi YS; Alotaibi S; Alonazi SH; Almutairi JM; Vishwakarma R
    J Infect Public Health; 2023 Sep; 16(9):1492-1499. PubMed ID: 37355406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the Clinical Prognosis of Critically Ill Patients with COVID-19 Admitted to Intensive Care Units: A Nationwide Saudi Study.
    Al Mutair A; Elhazmi A; Alhumaid S; Ahmad GY; Rabaan AA; Alghdeer MA; Chagla H; Tirupathi R; Sharma A; Dhama K; Alsalman K; Alalawi Z; Aljofan Z; Al Mutairi A; Alomari M; Awad M; Al-Omari A
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577801
    [No Abstract]   [Full Text] [Related]  

  • 6. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
    Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
    Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
    Alamer A; Alrashed AA; Alfaifi M; Alosaimi B; AlHassar F; Almutairi M; Howaidi J; Almutairi W; Mohzari Y; Sulaiman T; Al-Jedai A; Alajami HN; Alkharji F; Alsaeed A; Alali AH; Baredhwan AA; Abraham I; Almulhim AS
    Curr Med Res Opin; 2021 Jul; 37(7):1085-1097. PubMed ID: 33890544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and prognostic factors of intensive and non-intensive 1014 COVID-19 patients: an experience cohort from Alahsa, Saudi Arabia.
    Alhumaid S; Al Mutair A; Al Alawi Z; Al Salman K; Al Dossary N; Omar A; Alismail M; Al Ghazal AM; Jubarah MB; Al Shaikh H; Al Mahdi MM; Alsabati SY; Philip DK; Alyousef MY; Al Brahim AH; Al Athan MS; Alomran SA; Ahmed HS; Al-Shammari H; Elhazmi A; Rabaan AA; Al-Tawfiq JA; Al-Omari A
    Eur J Med Res; 2021 May; 26(1):47. PubMed ID: 34030733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary.
    Szabo BG; Lenart KS; Petrik B; Gaspar Z; Kiss-Dala N; Szlavik J; Valyi-Nagy I; Lakatos B;
    Geroscience; 2021 Oct; 43(5):2205-2213. PubMed ID: 34476717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: A descriptive cross-sectional study.
    Al-Omari A; Alhuqbani WN; Zaidi ARZ; Al-Subaie MF; AlHindi AM; Abogosh AK; Alrasheed AK; Alsharafi AA; Alhuqbani MN; Salih S; Alhedaithy MA; Abdulqawi R; Ismail AF; Alhumaid S; Hamdan N; Saad F; Olhaye FA; Eltahir TA; Alomari M; Alshehery M; Yassiri A; Al-Tawfiq JA; Al Mutair A
    J Infect Public Health; 2020 Nov; 13(11):1639-1644. PubMed ID: 33004305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of favipiravir in the treatment of COVID-19 based on the real-world.
    Deng W; Yang C; Yang S; Chen H; Qiu Z; Chen J
    Expert Rev Anti Infect Ther; 2022 Apr; 20(4):555-565. PubMed ID: 34846960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics.
    Elhazmi A; Rabie AA; Al-Omari A; Mufti HN; Sallam H; Alshahrani MS; Mady A; Alghamdi A; Altalaq A; Azzam MH; Sindi A; Kharaba A; Al-Aseri ZA; Almekhlafi GA; Tashkandi W; Alajmi SA; Faqihi F; Alharthy A; Al-Tawfiq JA; Melibari RG; Arabi YM
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study.
    Alharthy A; Aletreby W; Faqihi F; Balhamar A; Alaklobi F; Alanezi K; Jaganathan P; Tamim H; Alqahtani SA; Karakitsos D; Memish ZA
    J Epidemiol Glob Health; 2021 Mar; 11(1):98-104. PubMed ID: 33095982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
    Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
    J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV-2 infection in children, clinical characteristics, diagnostic findings and therapeutic interventions at a tertiary care center in Riyadh, Saudi Arabia.
    Alharbi M; Kazzaz YM; Hameed T; Alqanatish J; Alkhalaf H; Alsadoon A; Alayed M; Hussien SA; Shaalan MA; Al Johani SM
    J Infect Public Health; 2021 Apr; 14(4):446-453. PubMed ID: 33765595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
    Hassaniazad M; Farshidi H; Gharibzadeh A; Bazram A; Khalili E; Noormandi A; Fathalipour M
    J Med Virol; 2022 Jul; 94(7):3184-3191. PubMed ID: 35292989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
    Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA
    J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.